chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I started to feel headachy, feverish & over all malaise within 2 hors of vaccine. By 7pm my temp increased to 102 degrees - for more than 24 hrs - body aching terribly for 48 hrs+. Temp 100.2 at 50 hour post vaccine time despite analgesic.
Started with fever day after received FLUMIST and eye lids got puffy. About 10 days later started with red papular rash arms legs and buttock.
2 days after vaccines administered, pt. developed cough, vomiting & diarrhea persisting until at least 1/16/08.
Information has been received from a registered nurse concerning a 5 year old female with no pertinent medical history and no drug reactions allergies who on 7/5/06 at 11:30 AM was vaccinated SC with a 0.5ml dose of MMR II (lot 649758/0382R). Concomitant therapy that day at 11:30 AM included a dose of poliovirus vaccine and a dose of diphtheria toxoid + pertussis vaccine unspecified + tetanus toxoid. There were no other concomitant medication. On 7/5/06 at 1:18PM the patient came back to the office with vomiting, wheezing, and a rash. The child was given adrenalin at the office, and sent to the hospital with paramedics. At the ER, she was treated with diphenhydramine hydrochloride Benadryl IV, and kept overnight for observation. The parent said the rash started in the middle of her back and was not at the injection site. This was noted to be an anaphylactic reaction. On 7/11/06, the patient recovered from the anaphylactic reaction. The reporter would like a lot check for MMR II lot 649758/0382R. The records of testing prior to release of the lot in question have been rechecked and found to be satisfactory. The lot met the requirements of the Center for Biologics Evaluation and Research and was released by the regulatory agency. Anaphylactic reaction, wheezing and rash were considered to be immediately life threatening and other important medical events (OMIC). Additional information has been requested.
pt recv vax 17OCT94 & w/in 24 hr devel a viral synd w/fever, achiness & severe chills; began to exp visual problems & was dx w/bilat ischemic optic neuropathy; vision was substantially dec to 20/400 in rt eye & 20/40 in lt eye;
Left arm pain reported since receiving the flu shot (reported to health department 2/4/05). During follow up call, 2/7/05, from health department, Dad states child was evaluated and hospitalized. Medical Record received on 2/14/2005 states fever, decreased mobility and edema. 60 Day follow up: we have had no additional contact from childs family.
Covid bivalent vaccine not authorized after 09/12/2023, pt was given the vaccine on 09/13/2023.
Lump appeared immediately 1 1/2 in diameter. no shortness of breath, no numbness or tingling.  No treatment.
Patient complained of pain in left deltoid, visited physician one month later. Currently going to physical therapy. Physician has not said vaccination is result on continuing pain.
My arm was very sore almost immediately after injection. the next day my arm pit and left breast and area under left arm on body- were very swollen and sore. Maybe its the lymph nodes?  I couldn't lift my arm. 10 days later and feels better but still have swelling and pain, lessens every day
I developed a bad diarrhea after the vaccine booster on the day after administration. No issues previously with any other covid-19 vaccines. Extreme fatigue, nausea, headaches, and chills.
2nd dose earlier than recommended; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a male patient who received Herpes zoster (Shingrix) (batch number 333TE, expiry date 15th April 2023) for prophylaxis.   Concomitant products included RECOMBINANT VARICELLA ZOSTER VIRUS SURFACE GLYCOPROTEIN E (SHINGRIX).   On 10th November 2021, the patient received the 2nd dose of Shingrix. On 10th November 2021, unknown after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.  Additional details were reported as follows: The age at vaccination was not applicable for this report. The patient was not immunocompromised. The patient received the first dose of Shingrix on 15th October 2021. The patient received second dose of Shingrix earlier than recommended interval, which led to shortening of vaccination schedule. The reporter consented to follow up. This case has been linked to US2022040258, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022040258:Same reporter.
Pt received vaccine at 1130 on 4/10.  Per report of others reported feeling fine at 2300 4/10.  Went to bed.  Awoke at approx 0100 4/11, reported not feeling well, vomited, returned to bed.  Found by housemate at appox 2100 4/11 unresponsive.  Declared deceased with rigor mortis by EMS.  Pt in custody of the coroner for autopsy.
diaphoretic with increased temp (99.9), excessive cough, decreased oxygen saturation (84-88%) while on oxygen via nasal cannula. Lung sounds diminished upper lobes, mild wheezing to lower lobes.  increased oxygen via NC to 3 liters to maintain 90% SAT PRN DuoNeb tx started
6-17-21 date of vaccine at 5 pm patient became tired with body aches. 7pm extreme achyness. 9pm joint pain could not get comfortable while laying down. 11pm got fever. restless during the night. 7AM (6-18-21) fever of 100.5 with Tylenol. Patient stating still sore. Around 10:30AM fever broke patient feeling better but still tired and sore.
Went to local Pharmacy after work to get a Flu Shot (12-15-11). It was approximately 5:00/5:15pm. Filled out paperwork and Pharmacist administered Flu Shot. I went home and on with my evening. Woke from sleep at about 12:30 feeling not good. Went to the bathroom and looked at my face because my tongue felt stiff and my throat felt tight. Was kind of fuzzy because because I was sleep. Decided to go to hospital. Was taken to ER. They rushed me in and begin to administer, DECADRON, BENADRYL by IV and gave me PEPCID. Was kept a the ER until morning (12-16-11) for evaluation to make sure swelling had gone down. Was given RX to fill for, Ranitidine HCL, Prednisone and Diphenhydramine HCL. Filled Rx and started taking medications. On the third day (12-18-11), started feeling sick, unusual feeling, was taken back to ER. Test were run, Blood work, EKG, and Chest x-rays. They could find nothing wrong but they did tell me to stop taking the BENADRYL because I was dehydrated from the amount I was taking. Also my blood pressure was up quite a bit. Had doctors apt with my physician: 12-19-11 at 5:00pm. She instructed me to continue taking the Prednisone to completion and will have me make another apt for later unless I am having more problems. (12-20-11) I am on my last day of the Prednisone which is making me feel very bad and I am at work, I am also out of a lot of money due to the ER visits and lost time from work and not being able to participate and function during this time of year. Current Medications: I am currently on HBP medications and Sinus medications (spray) which I have been on for a couple years. Other than that I am okay. Go to the gym 2-3 x per week, work a full-time job. Note. I have had a flu shot before, about 3 years ago with no problems.
After client receive first dose of pfizer covid vaccination she c/o dizziness 15 minutes after dose was administered. She was assisted to lay on the cot, vitals was obtained, she then complained of n/v and a  stomachache.  VS T 97.1, BP 96/50, SPO2 99% RA, P 52.  She was then assisted on her side, legs was elevated. Next set of VS BP 139/75, P61, SPO2 98% RA.  Then she c/o having the chills. Next set of VS at 2:01 pm BP 166/64, P 65, SPO2 99% RA. She then stated that she was feeling better, final VS BS 163/73. Staff assisted her with getting home.
This is a spontaneous report received from a non-contactable reported  A 64-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 11Oct2022 as dose 4 (booster), single (Lot number: GJ6742) at the age of 64 years for covid-19 immunisation; BNT162b2 (BNT162B2), on 31Jan2021 as dose 1, single (Lot number: EL3247) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "COVID" (unspecified if ongoing), notes: if COVID prior vaccination: Yes. The patient took concomitant medications.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 31Dec2022, outcome "unknown" and all described as "+ Ag test 31Dec2022". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (31Dec2022) Positive, notes: Nasal Swab. It was unknown if therapeutic measures were taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible. No further information is expected.
Pt presented to the office in mild distress. Mom reported within 1-2 hours after vaccines, pt began having fever, chills, and h/a, and severe right upper arm pain at injection site of Meningococcal B. Mom gave MOTRIN to pt without improvement. H/a worsened to the point of crying so mom brought her to our after hours clinic. No bruising, swelling or redness noted to either injection site. Pt unable to tolerate h/a. Crying out loudly off and on in the office. She reported h/a 10 out of 0-10 on pain scale. C/o photophobia. Having rigors in office along with chills. Pt unable to lie flat without increasing headache. c/o nausea, no vomiting. Pt in so much pain, she began breathing too rapidly and EMS was called to transport her to ER.
Received Flu shot 10-20-08 Lot #01849111A Manufacturer CSL Biological on 10-20-08 c/o (R) Deltoid swollen, bruise and redness.
I was still having chest pain and breathing problems prior to getting it, so they wanted me to get the vaccine because if I got COVID, it would kill me. Over the weeks, my breathing worsened and I had terrible chest pains. They did another CT Scan to make sure I didn't have another embolism. The symptoms of my other conditions flared as well. I got the vaccine 3 or 4 days before the news was released about the blood clots. I'm still experiencing breathing issues, chest pains and dizziness. I'm now on additional meds for my lupus: Cymbalta and Lyrica. They're trying to help with the chest pain and polymyalgia. I was also given a Lidoderm patch to help with my chest pain. It just seems like everything got worse afterwards. I'm not sure if my lungs will ever function at 100% due to everything going on.
This case was considered medically important (OMIC). Information regarding FluMist was received from a consumer regarding a 9 year old male pt who developed pneumonia, the "flu," and hives. The pt received a dose on 12/31/2003. A consumer reported that her son "got the flu" on 1/3/04, three days post-immunization; he developed a fever of 103.3 deg F, severe coughing and vomiting and experienced chills and aches. He was treated with Tylenol. On 1/11/04, he developed "hives all over" and was diagnosed with pneumonia. He was treated with Biaxin, Benadryl, and an unspecified decongestant. He recovered. As of 1/26/04, no additional info was available.
Sudden onset of feeling hot, with body aches, then felt shaky, dizzy and panicky. Lasted less than 1 hour. Temp check 1 hour after onset reported @ 96.6  Did not seek medical attention, felt completely well in the morning, no visible reaction at the site of injection, no other symptoms.
Nerve pain started after the second vaccination. Felt in all 4 limbs. Strong, sharp, throbbing pain that comes and goes without warning or cause.
Developed moderate nausea and fever and severe headache, muscle soreness, and fatigue around 24 hours after receiving second dose of vaccine. Symptoms came on suddenly and required the patient to leave work (unable to complete daily activities). The symptoms were resolved by the morning of the following day.
This spontaneous case was reported by a consumer and describes the occurrence of JOINT STIFFNESS (Joints were stiff), ARTHRITIS (Felt like having major arthritis), MYALGIA (Lot of body aches) and ARTHRALGIA (Joints hurts when stands/Joints pops when stands) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 047A21A and 030M20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included MONTELUKAST SODIUM (SINGULAIR), CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY), Voltaren Gel, BACLOFEN and LIDOCAINE HYDROCHLORIDE (LIDOCAIN [LIDOCAINE HYDROCHLORIDE]) for an unknown indication.   On 19-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 18-Mar-2021, the patient experienced JOINT STIFFNESS (Joints were stiff), ARTHRITIS (Felt like having major arthritis), MYALGIA (Lot of body aches) and ARTHRALGIA (Joints hurts when stands/Joints pops when stands). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, JOINT STIFFNESS (Joints were stiff), ARTHRITIS (Felt like having major arthritis), MYALGIA (Lot of body aches) and ARTHRALGIA (Joints hurts when stands/Joints pops when stands) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient reported other concomitant medication as Lidocaine patch   Most recent FOLLOW-UP information incorporated above includes: On 13-Jul-2021: TCR was received does not contain any additional information patient ask not to contact her HCP
muscle aches, chills, fever, headache, exhaustion, thirst lasted approx. 30 hrs
Pt given DPT/HIB/MMR/OPV 930AM mom gave APAP q4hrs until 9PM then put to bed; Pt had extremely high fever @ 330AM; Temp not measured immediately given APAP & sponge bath; t101; Pt not taken to MD or ER;
injection site was extremely itchy; Initial information received on 12-Sep-2019 regarding an unsolicited valid non-serious case received from a other health professional (medical assistant).  This case involves an elderly female patient (age not reported) who experienced injection site was extremely itchy (vaccination site pruritus), while she received vaccine INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE lot number not reported via unknown route in unknown administration site.  On an unknown date, the patient developed a non-serious injection site was extremely itchy (vaccination site pruritus), unknown latency following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE. It was reported that this happened during the 2018-19 season and unclear during which month.  Other relevant tests were not reported.  Final diagnosis was injection site was extremely itchy.  It was not reported if the patient received a corrective treatment.  The outcome of the event was not reported.  Information on the batch number was requested.  List of documents held by sender: none.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. On 27-AUG-2014 the patient received a dose of M-M-R II (dose, route not reported, lot # J009706, expiration date 15-AUG-2015) exposed to temperatures outside of the proper storage range. Concomitant medications were not provided. No adverse effect was reported. This is one of several reports received from the same reporter. Additional information has been requested.
Increasing muscle pain to touch at left shoulder injection site.   Losing mobility of left arm from pain only, 24hrs after injection: Moderna Jab-1  No external swelling, or inflammation, no change to lymph nodes under arm. No work or activity, since injection. Gentle massage of left shoulder only.
weakness; muscle pain; sore at the injection site; Fever; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (weakness), MYALGIA (pain) and VACCINATION SITE PAIN (sore at injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ASTHENIA (weakness), MYALGIA (pain) and VACCINATION SITE PAIN (sore at injection site). At the time of the report, ASTHENIA (weakness), MYALGIA (pain) and VACCINATION SITE PAIN (sore at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.   This case was linked to MOD-2021-017165 (Patient Link).
My right eye bottom eyelid swollen and very sensitive and painful. Took two rounds of Benadryl yesterday and will be taking more today.
aches/Pain; Chills; fatigued; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (aches/Pain), CHILLS (Chills) and FATIGUE (fatigued) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in November 2020. Concomitant products included VENLAFAXINE HYDROCHLORIDE (EFFEXOR) and VITAMINS NOS (DAILY VITAMINS) for an unknown indication.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, the patient experienced PAIN (aches/Pain) and FATIGUE (fatigued). 02-Mar-2021, the patient experienced CHILLS (Chills). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, PAIN (aches/Pain), CHILLS (Chills) and FATIGUE (fatigued) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In November 2020, SARS-CoV-2 test: positive (Positive) Positive. In February 2021, SARS-CoV-2 antibody test: 12.5 (Inconclusive) Inconclusive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient stated that she stayed in bed for several days.   Reporter did not allow further contact
This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. The patient had no pertinent medical history and no drug reactions/allergies. There were no concomitant medications. On 25-SEP-2016, the patient was vaccinated with a dose of PNEUMOVAX23 lot # M027552 with an expiration date: 04-FEB-2018 for prophylaxis (dose, route of vaccination and anatomical location were not reported). On 26-SEP-2016, reported as about one day after receiving the vaccine, the patient experienced cellulitis, swelling and inflammation about 2 inches below the injection site. The patient sought medical attention and visited physician. The patient was given unspecified antibiotics for the event. The outcome of cellulitis, inflammation and swelling was unknown. No lab diagnostics studies were performed. The relatedness between the events and vaccination PNEUMOVAX23 was not reported. Upon internal review cellulitis was determined to be medically significant. This is one of two reports from the same source. Follow up information has been received on 25-OCT-2016 from the pharmacist. Patient demographics were updated (83 year old male). On 25-SEP-2016, at 11 am, the patient received first dose of PNEUMOVAX23 intramuscularly on his left deltoid. On the same day at 13:00 he experienced cellulitis, inflammation and swelling. On 27-SEP-2016, the patient recovered from the events cellulitis, inflammation and swelling. Follow up information has been received on 10-JAN-2017. An investigation into the manufacture of lot M027552 was completed and confirmed that all in-process quality checks were satisfactory. The results indicated that the lot was manufactured in accordance with manufacturing site standard operating procedures. The lot was confirmed to have met the requirements for market release. Following medical review of the AE report and the Quality investigation, there were no identified concerns related to quality within the results of the investigation. Additional information is not expected as all correspondence was received. Product and narrative were updated. Sender's Comments: US-009507513-1609USA013332: MERCK 1609USA014340: Mfr number.
I fainted almost immediately but I was extremely anxious and crying/hyperventilating. I also had nausea and retching, My blood pressure went up.  A couple of hours later I had a sever head ache, chills and sweats with body aches that lasted through the next morning.
Information has been received from a consumer concerning her son, an approximately 33 months old male twin with no allergies or medical history who was vaccinated with a dose of MMR II. There was no concomitant medication. The reporter indicated that she found out that the pt had autism in March 2002. The pt was tested by a neurologist. The neurologist stated that the pt did not "have the gene for it." A DNA probe was conducted for Fragile X. It was noted that the pt does not talk at all and is in a speech school. The reporter also indicated that he does not understand potty training, cannot take his shoes off, and has a hard time getting dressed. The mother noted that he has no emotions for someone else's feelings and "if you're crying he doesn't look at you." Therapy with MMR II was discontinued. The pt's autism persisted. It was noted that a prescription drug was not required. A product quality complaint was not involved. The pt's mother felt that autism was considered to be disabling. Additional info has been requested. The reporter also indicated that the pt's twin sister experienced an adverse event after therapy with MMR II (WAES0310USA02920). A 15-day follow up report received 12/12/2003 adds: Follow-up info from the physician's office indicated that it could not be found in the pt's chart when it was first noted that the pt had difficulty with speech. The pt had been seen by a gastroenterologist in Sept 2000 for vomiting of solid food. The pt had been sent to a neurologist in April 2003, but it could not be found in the chart where the pt had been diagnosed with autism as reported by the mother. The neurology visit had been scheduled because of a visit in 2002 where it was documented that the pt was active in the exam room, however he was not talking and did not make eye contact. At the age of 3 years the pt was being seen at a developmental center for speech therapy. The pt's mother felt that autism was considered to be disabling. Additional info is not expected. The reporter also indicated that the pt's twin sister experienced an adverse event after therapy with measles virus vaccine live (Moraten) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3) (WAES #0310USA02920).
Pt reported feeling a rush through his body. approximately 7 minutes post vaccination.  In addition, he also reported feeling flushed and that his heart was beating so fast. VS initiated, not WNL. hypertensive and tachycardic. pulsations noted in the abdominal region. Pt also reported feeling a tingling sensation in the left arm(site of administration) HR & BP remained elevated. EMS called. Pt transferred to the care of EMS approximately 50 minutes after reporting symptoms.
Pfizer-BioNTech COVID- 19 Vaccine EUA: After receiving vaccination, patient became lightheaded and diaphoretic. Patient hypertensive. Patient recovered with no intervention and ambulated out of building with assistance from nursing student. EMS monitored patient for 30 minutes, no intervention required.